140 related articles for article (PubMed ID: 34029636)
1. Build to understand biliary oncogenesis via organoids and FGFR2 fusion proteins.
Boulter L; Ebrahimkhani MR
J Hepatol; 2021 Aug; 75(2):262-264. PubMed ID: 34029636
[No Abstract] [Full Text] [Related]
2. FGFR2 fusion proteins drive oncogenic transformation of mouse liver organoids towards cholangiocarcinoma.
Cristinziano G; Porru M; Lamberti D; Buglioni S; Rollo F; Amoreo CA; Manni I; Giannarelli D; Cristofoletti C; Russo G; Borad MJ; Grazi GL; Diodoro MG; Giordano S; Sacconi A; Forcato M; Anastasi S; Leonetti C; Segatto O
J Hepatol; 2021 Aug; 75(2):351-362. PubMed ID: 33741397
[TBL] [Abstract][Full Text] [Related]
3. [Cancer Therapy Targeting Fusion Gene(FGFR2 Fusion Gene)in Biliary Tract Cancer].
Hamaguchi T; Ueno M
Gan To Kagaku Ryoho; 2022 Oct; 49(10):1040-1042. PubMed ID: 36281591
[TBL] [Abstract][Full Text] [Related]
4. Identification of cancer-related genes FGFR2 and CEBPB in choledochal cyst via RNA sequencing of patient-derived liver organoids.
Ye Y; Lui VCH; Babu RO; Wu Z; Wu W; Chung PHY; Wong KKY; Wang B; Tam PKH
PLoS One; 2023; 18(3):e0283737. PubMed ID: 36996081
[TBL] [Abstract][Full Text] [Related]
5. Inhibitor-sensitive FGFR2 and FGFR3 mutations in lung squamous cell carcinoma.
Liao RG; Jung J; Tchaicha J; Wilkerson MD; Sivachenko A; Beauchamp EM; Liu Q; Pugh TJ; Pedamallu CS; Hayes DN; Gray NS; Getz G; Wong KK; Haddad RI; Meyerson M; Hammerman PS
Cancer Res; 2013 Aug; 73(16):5195-205. PubMed ID: 23786770
[TBL] [Abstract][Full Text] [Related]
6. Characterization of a KLK2-FGFR2 fusion gene in two cases of metastatic prostate cancer.
Krook MA; Barker H; Chen HZ; Reeser JW; Wing MR; Martin D; Smith AM; Dao T; Bonneville R; Samorodnitsky E; Miya J; Freud AG; Monk JP; Clinton SK; Roychowdhury S
Prostate Cancer Prostatic Dis; 2019 Dec; 22(4):624-632. PubMed ID: 31043681
[TBL] [Abstract][Full Text] [Related]
7. Involvement of fibroblast growth factor receptor 2 isoform switching in mammary oncogenesis.
Cha JY; Lambert QT; Reuther GW; Der CJ
Mol Cancer Res; 2008 Mar; 6(3):435-45. PubMed ID: 18337450
[TBL] [Abstract][Full Text] [Related]
8. Functions of FGFR2 corrupted by translocations in intrahepatic cholangiocarcinoma.
Li F; Peiris MN; Donoghue DJ
Cytokine Growth Factor Rev; 2020 Apr; 52():56-67. PubMed ID: 31899106
[TBL] [Abstract][Full Text] [Related]
9. Generation of An Endogenous FGFR2-BICC1 Gene Fusion/58 Megabase Inversion Using Single-Plasmid CRISPR/Cas9 Editing in Biliary Cells.
Reicher A; Harris AL; Prinz F; Kiesslich T; Wei M; Öllinger R; Rad R; Pichler M; Kwong LN
Int J Mol Sci; 2020 Apr; 21(7):. PubMed ID: 32252259
[TBL] [Abstract][Full Text] [Related]
10. The breast cancer susceptibility gene product fibroblast growth factor receptor 2 serves as a scaffold for regulation of NF-κB signaling.
Wei W; Liu W; Cassol CA; Zheng W; Asa SL; Ezzat S
Mol Cell Biol; 2012 Nov; 32(22):4662-73. PubMed ID: 22988296
[TBL] [Abstract][Full Text] [Related]
11. miR‑494 inhibits cancer‑initiating cell phenotypes and reverses resistance to lapatinib by downregulating FGFR2 in HER2‑positive gastric cancer.
Yu Y; Yu X; Liu H; Song Q; Yang Y
Int J Mol Med; 2018 Aug; 42(2):998-1007. PubMed ID: 29786108
[TBL] [Abstract][Full Text] [Related]
12. The Co-mutational Spectrum Determines the Therapeutic Response in Murine FGFR2 Fusion-Driven Cholangiocarcinoma.
Kendre G; Marhenke S; Lorz G; Becker D; Reineke-Plaaß T; Poth T; Murugesan K; Kühnel F; Woller N; Wirtz RM; Pich A; Marquardt JU; Saborowski M; Vogel A; Saborowski A
Hepatology; 2021 Sep; 74(3):1357-1370. PubMed ID: 33709535
[TBL] [Abstract][Full Text] [Related]
13. Aberrant hypermethylation of the FGFR2 gene in human gastric cancer cell lines.
Park S; Kim JH; Jang JH
Biochem Biophys Res Commun; 2007 Jun; 357(4):1011-5. PubMed ID: 17459342
[TBL] [Abstract][Full Text] [Related]
14. Novel FGFR2-INA fusion identified in two low-grade mixed neuronal-glial tumors drives oncogenesis via MAPK and PI3K/mTOR pathway activation.
Jain P; Surrey LF; Straka J; Luo M; Lin F; Harding B; Resnick AC; Storm PB; Buccoliero AM; Santi M; Li MM; Waanders AJ
Acta Neuropathol; 2018 Jul; 136(1):167-169. PubMed ID: 29767381
[No Abstract] [Full Text] [Related]
15. Molecular detection and clinicopathological characteristics of advanced/recurrent biliary tract carcinomas harboring the FGFR2 rearrangements: a prospective observational study (PRELUDE Study).
Maruki Y; Morizane C; Arai Y; Ikeda M; Ueno M; Ioka T; Naganuma A; Furukawa M; Mizuno N; Uwagawa T; Takahara N; Kanai M; Asagi A; Shimizu S; Miyamoto A; Yukisawa S; Kadokura M; Kojima Y; Furuse J; Nakajima TE; Sudo K; Kobayashi N; Hama N; Yamanaka T; Shibata T; Okusaka T
J Gastroenterol; 2021 Mar; 56(3):250-260. PubMed ID: 33106918
[TBL] [Abstract][Full Text] [Related]
16. Differential signal transduction of alternatively spliced FGFR2 variants expressed in human mammary epithelial cells.
Moffa AB; Ethier SP
J Cell Physiol; 2007 Mar; 210(3):720-31. PubMed ID: 17133345
[TBL] [Abstract][Full Text] [Related]
17. Fibroblast Growth Factor Receptor 2 Signaling in Breast Cancer.
Lei H; Deng CX
Int J Biol Sci; 2017; 13(9):1163-1171. PubMed ID: 29104507
[TBL] [Abstract][Full Text] [Related]
18. Pemigatinib in cholangiocarcinoma with a FGFR2 rearrangement or fusion.
Storandt MH; Jin Z; Mahipal A
Expert Rev Anticancer Ther; 2022 Dec; 22(12):1265-1274. PubMed ID: 36408971
[TBL] [Abstract][Full Text] [Related]
19. FGF18-FGFR2 signaling triggers the activation of c-Jun-YAP1 axis to promote carcinogenesis in a subgroup of gastric cancer patients and indicates translational potential.
Zhang J; Wong CC; Leung KT; Wu F; Zhou Y; Tong JHM; Chan RCK; Li H; Wang Y; Yan H; Liu L; Wu WKK; Chan MWY; Cheng ASL; Yu J; Wong N; Lo KW; To KF; Kang W
Oncogene; 2020 Oct; 39(43):6647-6663. PubMed ID: 32934314
[TBL] [Abstract][Full Text] [Related]
20. Prognostic impact of FGFR2/3 alterations in patients with biliary tract cancers receiving systemic chemotherapy: the BITCOIN study.
Rizzato M; Brignola S; Munari G; Gatti M; Dadduzio V; Borga C; Bergamo F; Pellino A; Angerilli V; Mescoli C; Guido M; Rearden J; Gringeri E; Cillo U; Dei Tos AP; Zagonel V; Loupakis F; Lonardi S; Fassan M
Eur J Cancer; 2022 May; 166():165-175. PubMed ID: 35303508
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
